Form 4: Sonnet BioTherapeutics CFO Granted Significant Equity Award

Sonnet BioTherapeutics Holdings, Inc. Chief Financial Officer and Director Donald J. Griffith was granted 10,000 restricted stock units, increasing his beneficial ownership to 10,375 shares.

Summary

• Donald J. Griffith, Chief Financial Officer and Director of Sonnet BioTherapeutics Holdings, Inc., acquired 10,000 restricted stock units (RSUs) on July 11, 2025.
• These restricted stock units will be settled in shares of common stock, par value $0.0001.
• The RSUs vest 100% on the earlier of January 8, 2026, or the date of a "Change in Control" as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.
• Following this transaction, Donald J. Griffith beneficially owns a total of 10,375 shares, which includes these unvested restricted stock units.
• All reported amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive sign of alignment between management and shareholder interests, though it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 10,000 restricted stock units to the Chief Financial Officer and Director, Donald J. Griffith, aligns management's interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule, tied to either a specific date (January 8, 2026) or a Change in Control, provides clear incentives for retention and strategic outcomes for a key executive.

Negatives

• NA

Risks

• NA

Future Outlook

The restricted stock units granted to Donald J. Griffith are scheduled to vest 100% on the earlier of January 8, 2026, or the date of a "Change in Control" as defined under the Issuer's 2020 Omnibus Equity Incentive Plan.

Management Comments

• NA

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 10,000 restricted stock units to Donald J. Griffith, the Chief Financial Officer and Director, constitutes a transaction with a related party as part of his compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the interests of the Chief Financial Officer with shareholders, potentially leading to better long-term performance and value creation.
• Management: The grant serves as an incentive for retention and performance for the Chief Financial Officer.

Next Steps

• Vesting of 10,000 restricted stock units on the earlier of January 8, 2026, or a Change in Control.

Key Dates

Keywords

Sonnet BioTherapeutics, SONN, Form 4, insider transaction, restricted stock units, RSU, equity grant, Donald J. Griffith, Chief Financial Officer, Director, beneficial ownership, reverse stock split